| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
MYCMI-6 (NSC354961) (6.25 μM; 48 hours) suppresses the development of tumor cells driven by MYC in an effective and precise manner [1]. Burkitt-located cells (Mutu, Daudi, and ST486) are another well-known example of MYC-driven malignancies. MYC easily localizes to one of the immunoglobulin sites in a dose-dependent manner, with an average GI50 of 0.5 μM. MYCMI-6 greatly slows the growth of these cells. Following a 24-hour treatment with MYCMI-6 for MCF7 cells, titration revealed a considerable reduction in the MYC:MAX isPLA signal, indicating that the IC50 of PLA inhibition of MYC:MAX versus MYCMI-6 was less than 1.5 μM. MYCMI-6 has an IC50 of 3.8 μM, which inhibits the production of MYC:MAX heterodimers. With an IC50, MYCMI-6 potently inhibits MYCN in neuroblasts. 7 percent. Tumor cell proliferation that is anchorage-independent has a GI50 value of less than 0.4 μM [1].
|
|---|---|
| ln Vivo |
In a MYC-requiring xenograft tumor model, MYCMI-6 (20 mg/kg; i.p.; once daily for 1-2 weeks) decreases tumor cell swelling, tumor microvessel density, and MYC:MAX interactions while inducing severe cellular ischemia.
|
| Cell Assay |
Cell viability assay[1]
Cell Types: MYCN-amplified neuroblastoma cells (IMR-32, Kelly and SK-N-DZ), MYCN-non-amplified neuroblastoma cells (SK-N-F1, SK -N-AS and SK-N-RA) Tested Concentrations: 6.25 μM Incubation Duration: 48 hrs (hours) Experimental Results: The growth reduction of MYCN-amplified cell lines was Dramatically stronger than that of MYCN-amplified non-amplified cell lines. |
| Animal Protocol |
Animal/Disease Models: 6-8 weeks old athymic nude mice (SK-N-DZ neuroblastoma cells carrying MYCN amplification) [1]
Doses: 20mg/kg body weight Route of Administration: Ip; effect [1]. one time/day for 1-2 weeks Experimental Results: There was a significant increase in the expansion of apoptotic areas and a significant increase in non-proliferative areas in the tumors as determined by Ki67 staining in the tumors. |
| References |
| Molecular Formula |
C20H19N7O
|
|---|---|
| Molecular Weight |
373.411
|
| Exact Mass |
373.165
|
| CAS # |
681282-09-7
|
| Related CAS # |
1093100-07-2 (2HCl);681282-09-7;
|
| PubChem CID |
434695
|
| Appearance |
Brown to reddish brown solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
547
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC1C2=C(C=C(/N=N/C3=CC=C(N)N=C3N)C=C2)N=C2C=1C=C(OCC)C=C2
|
| InChi Key |
QNWGRUNKGVWOTA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19N7O/c1-2-28-12-4-6-15-14(10-12)19(22)13-5-3-11(9-17(13)24-15)26-27-16-7-8-18(21)25-20(16)23/h3-10H,2H2,1H3,(H2,22,24)(H4,21,23,25)
|
| Chemical Name |
3-[(9-amino-7-ethoxyacridin-3-yl)diazenyl]pyridine-2,6-diamine
|
| Synonyms |
MYCMI6; MYCMI 6
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2.4 mg/mL (~6.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6780 mL | 13.3901 mL | 26.7802 mL | |
| 5 mM | 0.5356 mL | 2.6780 mL | 5.3560 mL | |
| 10 mM | 0.2678 mL | 1.3390 mL | 2.6780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
